




RealRate

PHARMACEUTICAL 2017

Nabriva Therapeutics plc
Rank 179 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Nabriva Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nabriva Therapeutics plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 213% points. The greatest weakness of Nabriva Therapeutics plc is the variable Other Expenses, reducing the Economic Capital Ratio by 295% points.

The company's Economic Capital Ratio, given in the ranking table, is -252%, being 164% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	90,621
Cost of Goods Sold	0
Intangible Assets	270
Liabilities, Current	15,877
Liabilities, Non-Current	107
Other Assets	1,830
Other Compr. Net Income	50
Other Expenses	47,397
Other Liabilities	0
Other Net Income	6,042
Property and Equipment	519
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	13,535

Output Variable	Value in 1000 USD
Assets	93,240
Liabilities	15,984
Expenses	60,932
Stockholders Equity	77,256
Net Income	-54,890
Comprehensive Net Income	-54,865
Economic Capital Ratio	-252%